Appointment of Financial Adviser for Strategic Review

• Chimeric Therapeutics has appointed Hawkesbury Partners as its Independent Financial Adviser
• The review aims to maximize shareholder value
• Potential strategic options include partnerships, funding, licensing, and mergers

Chimeric Therapeutics Limited, a leading Australian cell therapy company, has appointed Hawkesbury Partners Pty Limited as its Independent Financial Adviser to undertake a strategic review aimed at maximizing shareholder value. The Board believes the value embedded in Chimeric's clinical programs and infrastructure is not currently reflected in the Company's market capitalization. Hawkesbury Partners' mandate includes identifying and evaluating opportunities to monetize and realize value for Chimeric, potentially through strategic partnerships, funding, licensing arrangements, co-development agreements, mergers, asset sale transactions, and alternative capital structures.